1. Riess J.G., Flaim S.F., Klein D.H., Weers J.G. 1995. The relative physicochemical and biological atrtributes of perflubron emulsions. In: Perfluorocarbon compounds in biology and medicine. Ed. Ivanitsky G.R., Moroz V.V. Pushchino, p. 73–90.
2. Coch C.S., Cushing M.M. 2009. Oxygen therapeutics: Perfluorocarbons and blood substitute safety. Crit. Care Clin.
25, 399–414. https://doi.org/10.1016/j.ccc.2008.12.007
3. Henkel-Hanke T., Oleck M. 2007. Artificial oxygen carriers: A current review. Am. As. Nurse Anest. J.
75 (3), 205–211.
4. Mayevsky E.I., Aksenova O.G., Bogdanova L.A., Ivanitsky G.R. 2004. Analysis of side clinical effects identified during phase I–II clinical trials of Perfluorane. Vestnik sluzhbi krovi Rossii (Rus.). 4, 23–29.
5. Vercellotti G.M., Hammerschmidt D.E., Craddock P.R., Jacob H.S. 1982. Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale corticosteroids prophylaxis. Blood.
59, 1299–1304.